Lv1
44 积分 2023-02-01 加入
A first-in-human, phase 1a dose-escalation study of the selective MEK1/2 inhibitor FCN-159 in patients with advanced NRAS-mutant melanoma
7小时前
已完结
Long-term MAPK inhibition of childhood refractory-Langerhans cell histiocytosis: an observational study of 288 patients
10天前
已完结
Personalized Selumetinib Dosing in Pediatric Neurofibromatosis Type 1: Insights From a Pilot Therapeutic Drug Monitoring Study
2个月前
已完结
Cutaneous Adverse Drug Reactions Associated With BRAF and MEK Inhibitors: A Real‐World Analysis of WHO Pharmacovigilance Data
2个月前
已完结
A phase 2 study of the MEK1/2 inhibitor luvometinib in patients with extracranial arteriovenous malformations
3个月前
已完结
Phase 1 Study of Luvometinib Use in Pediatric Patients with Neurofibromatosis Type 1-Related Unresectable Plexiform Neurofibromas
7个月前
已完结
Unstuck and on target! for children with neurofibromatosis type 1: a feasibility and acceptability study
8个月前
已完结
Phase 1 Study of Luvometinib Use in Pediatric Patients with Neurofibromatosis Type 1-Related Unresectable Plexiform Neurofibromas
8个月前
已关闭
A national modified Delphi consensus on the referral and management of NF1 plexiform neurofibroma
8个月前
已完结
Phase 1 Study of Luvometinib Use in Pediatric Patients with Neurofibromatosis Type 1-Related Unresectable Plexiform Neurofibromas
8个月前
已关闭
皖公网安备34019202002308
